VCP R155H

# Research Brief: VCP R155H Variant ## Pathogenic Mechanisms The VCP R155H variant disrupts multiple critical cellular pathways fundamental to protein homeostasis and cellular stress responses. VCP (Valosin-containing protein) functions as an AAA+ ATPase critical for protein quality control, with core molecular functions including ATP binding, ATP hydrolysis, and interactions with essential cofactors (NSFL1C, UBXN6, UBXN2A, UBXN7, ASPSCR1). Literature findings reveal that VCP mutations, including R155H, induce pathogenic mechanisms spanning hypoxic stress responses in astrocytes, protein quality control dysfunction, and synucleinopathy. The R155H substitution likely destabilizes VCP domain structure, compromising its role in autophagosome maturation and aggresome assembly—processes essential for clearing misfolded proteins. This structural destabilization appears to create a toxic gain-of-function phenotype rather than simple loss of activity, as evidenced by the accumulation of protein aggregates and impaired autophagy observed in affected tissues. The variant's location and the mechanistic studies position VCP as both a disease driver in multisystem proteinopathies and a critical node where multiple degradation pathways converge. ## Clinical Significance The R155H variant is associated with inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD), a multisystem proteinopathy that can also present with amyotrophic lateral sclerosis (ALS) features. Clinical registry data document the progressive nature of these conditions, with the phenotypic spectrum expanding beyond the classical triad to include variable combinations of neurodegenerative and musculoskeletal manifestations. The pathogenicity of R155H reflects its impact on VCP's essential cellular functions, with patients exhibiting progressive muscle weakness, bone remodeling abnormalities, and cognitive decline. The variant demonstrates how disruption of a single protein quality control hub can manifest as tissue-selective pathology across multiple organ systems, likely reflecting differential dependencies on VCP function in muscle, bone, and neural tissues. ## Therapeutic Landscape Therapeutic development for VCP R155H faces the challenge of targeting a protein central to multiple cellular pathways. Computational analysis identifies an aggregation hotspot at residues 265-269 (aggregation score: 0.80), suggesting this region as a potential target for aggregation-modulating interventions. The therapeutic strategy may benefit from approaches that either stabilize VCP's native conformation to prevent the structural destabilization caused by R155H, or enhance compensatory protein quality control pathways to manage the accumulation of misfolded substrates. Small molecules targeting VCP's ATPase activity or cofactor interactions represent potential avenues, though careful titration would be necessary given VCP's essential cellular functions. The identification of VCP as both a disease driver and therapeutic target suggests that partial functional modulation, rather than complete inhibition, may offer the optimal therapeutic window. ## Research Directions Critical knowledge gaps remain in understanding tissue-specific vulnerabilities to VCP R155H dysfunction. Key research priorities include: (1) determining why muscle, bone, and frontal cortex are preferentially affected despite ubiquitous VCP expression; (2) identifying the specific VCP substrates whose accumulation drives pathology in each tissue type; (3) characterizing how the R155H variant alters VCP's interaction network with its cofactors and substrates; (4) developing biomarkers for early disease detection and progression monitoring; and (5) testing whether enhancing alternative protein degradation pathways (proteasome, chaperone-mediated autophagy) can compensate for impaired VCP function. Additionally, structural studies examining R155H's precise impact on VCP hexamer formation and ATPase cycling would provide crucial insights for rational drug design. Patient-derived cellular models and disease registries will be essential for correlating molecular mechanisms with clinical phenotypes and identifying therapeutic response predictors.